Skip to main content

Table 2 Hazard ratios (HR) with 95 % CI for the association between death and treatment type

From: Increased survival with the combination of stereotactic radiosurgery and gefitinib for non-small cell lung cancer brain metastasis patients: a nationwide study in Taiwan

Treatment type

Median SYa

cHR (95 % CI)

aHR (95 % CI)

WBRT

0.53

1.00 (reference)

1.00 (reference)

WBRT+ gefitinib

1.01

0.56 (0.62-0.68)*

0.73 (0.70-0.78)*

WBRT + GK

1.46

0.43 (0.34-0.54)*

0.49 (0.36-0.66)*

WBRT+ gefitinib + GK

2.25

0.40 (0.30-0.52)*

0.42 (0.30-0.59)*

  1. cHR: crude HR; aHR: adjust for age, sex, CCI
  2. aMedian SY, median survival year
  3. *p < 0.0001
Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us